SEK 0.18
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Immunovia AB (publ) is a diagnostics company focused on developing and marketing blood tests, serving both Swedish and international markets. Its key offering is IMMray PanCan-d, a specialized blood test designed to facilitate the early diagnosis of pancreatic cancer. The company also pursues research initiatives concerning lung cancer. Established in 2007, Immunovia's main office is located in Lund, Sweden.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Data is available to registered users only